Organic Acids
Medchemexpress LLC VTP-27999 TFA | 1013937-63-7 | 97.00% | C28H42ClF3N4O7 | 25 MG
VTP-27999 TFA is a potent alkyl amine Renin inhibitor, recognized for its role in addressing hypertension and related end-organ diseases. This compound is primarily utilized in research settings to explore the mechanisms of renin-angiotensin-aldosterone system (RAAS) regulation. Its specific inhibitory action offers a valuable tool for studying cardiovascular conditions and developing novel therapeutic strategies.
- Potent alkyl amine renin inhibitor
- Useful for hypertension research
- Applicable in studies of end-organ diseases
- Supports research on RAAS regulation
- Aids in the development of cardiovascular therapies
Medchemexpress LLC QL47B TFA | 96.0% | 992.07 | 1 MG
QL47B TFA is a biotinylated analogue of QL47, functioning as a potent inhibitor of BTK with an IC50 value of 1.3 μM. It has demonstrated anti-tumor activity.
- Potent inhibitor of BTK (IC50 value of 1.3 μM)
- Biotinylated analogue
- Exhibits anti-tumor activity
- Available in various pack sizes
- Purity of 96.03%
Medchemexpress LLC Lys-CoA TFA (Lys-coenzyme A) | 98.5% | 1 MG
Lys-CoA TFA is a selective p300 histone acetyltransferase (HAT) inhibitor with an IC50 of 50-500 nM. It demonstrates over 100-fold selectivity for p300 compared to PCAF (IC50=200 μM). This compound works by inhibiting p300 HAT activity-dependent transcriptional activation.
- Selective p300 histone acetyltransferase (HAT) inhibitor
- IC50 of 50-500 nM for p300
- Over 100-fold selectivity for p300 compared to PCAF
- Induces a senescent phenotype in human normal melanocytes at 0.1 and 1 mM concentrations
- Inhibits cyclin E expression in a dose-dependent manner
Medchemexpress LLC Apstatin TFA | 99.4% | 25 MG
Apstatin TFA is a potent aminopeptidase P (APP) inhibitor. It exhibits Ki values of 2.6 μM for rat APP and 0.64 μM for human APP. This compound has also demonstrated cardioprotective effects.
- Potent aminopeptidase P (APP) inhibitor
- Effective at 2.6 μM for rat APP
- Effective at 0.64 μM for human APP
- Shows cardioprotection
- Reduces myocardial infarct size in acute myocardial ischemia models
- For research use only
Medchemexpress LLC TfR-T12 TFA | 99.1% | 1604.75 | 1 MG
TfR-T12 TFA is a BBB-penetrated transferrin receptor (TfR) binding peptide. It binds to the TfR and is subsequently internalized into TfR-expressing cells, making it suitable for research applications.
- Displays a binding affinity in the nM range.
- Synthetic peptide obtained by phage display.
- Binds to a different site on TfRs compared with transferrin.
- Can be chemically conjugated to construct multifunctional lipid vesicles.
Medchemexpress LLC NLS-StAx-h TFA | 2872559-21-0 | 98.9% | 3559.28 | 100 UG
NLS-StAx-h TFA is a selective, cell-permeable, stapled peptide Wnt signaling inhibitor with an IC50 of 1.4 μM. It efficiently inhibits β-catenin-transcription factor interactions and demonstrates anti-proliferation effects on cancer cells, making it suitable for research into Wnt signaling pathways.
- Efficiently inhibits β-catenin-transcription factor interactions
- Shows anti-proliferation effects on cancer cells
- Reduces the viability of SW-480 and DLD-1 colorectal cancer cells by more than 80%
- Inhibits the migration of colorectal cancer cells in a dose-dependent manner
Medchemexpress LLC JBJ-09-063 TFA | 99.6% | 670.67 | 5 MG
JBJ-09-063 TFA is a mutant-selective allosteric EGFR inhibitor with IC50s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. It effectively reduces EGFR, Akt and ERK1/2 phosphorylation and is effective across EGFR tyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 TFA can be used for researching EGFR-mutant lung cancer.
- Effectively inhibits cell growth and increases apoptosis, even in gefitinib-resistant H3255GR cells with an EGFR T790M mutation.
- Shows efficacy in H1975 cells expressing osimertinib-resistant mutations.
- Exhibits IC50s of 50 nM and 6 nM in Ba/F3 cell when used alone or in combination.
- Has favorable pharmacokinetic properties and good efficacy upon oral dosing.
Medchemexpress LLC Goralatide TFA | 1796568-94-9 | 98.0% | 1 MG
Goralatide TFA is an inhibitor of cell cycle progression that enhances the selectivity of hyperthermic purging of human progenitor cells. It has potential for research related to leukemia.
- Inhibits cell cycle progression.
- Enhances selectivity of hyperthermic purging of human progenitor cells.
- Potential for leukemia research.
Medchemexpress LLC ALX-1393 TFA | 949164-09-4 | 99.8% | 509.45 | 50 MG
ALX-1393 TFA is a selective glycine transporter-2 (GlyT2) inhibitor that demonstrates an antinociceptive effect, meaning it helps reduce pain. This compound has been observed to alleviate pain responses to thermal, mechanical, and chemical stimulations in a rat acute pain model. In experimental settings, administration of the compound has been shown to suppress the late-phase response in the formalin test and inhibit mechanical and cold hyperalgesia in a dose-dependent manner, without affecting motor performance in normal rats.
- Selectively inhibits a specific neuronal transporter.
- Exhibits pain-reducing effects across various types of pain stimuli.
- Effective in inflammatory and neuropathic pain models.
- Does not impair motor function.
Medchemexpress LLC OS-2966 5mg | 5mg
OS-2966 is a humanized antibody expressed in CHO cells targeting Integrin b1/ITGB1/CD29 OS-2966 carries a huIgG1 type heavy chain and a hu type light chain with a predicted molecular weight (MW) of 145 5 kDa The isotype control for OS-2966 can be referenced as Human IgG1 kappa Isotype Control (HY-P99001)
Medchemexpress LLC ALX-1393 TFA | 99.8% | 509.45 | 25 MG
ALX-1393 TFA is a selective GlyT2 inhibitor that demonstrates an antinociceptive effect against thermal, mechanical, and chemical stimulations in a rat acute pain model.
- Selective GlyT2 inhibitor
- Exhibits an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model
Medchemexpress LLC PBX-7011 TFA | 98.6% | 561.46 | 1 MG
PBX-7011 TFA is a derivative of camptothecin, which inhibits the expressions of cancer-related survival genes DDX5, Survivin, Mcl-1, and XIAP in FaDu cells. It degrades DDX5 proteins and exhibits anticancer activity. This product is for research use only and not sold to patients.
- Inhibits expression of cancer-related survival genes DDX5, Survivin, Mcl-1, and XIAP.
- Degrades DDX5 proteins.
- Exhibits anticancer activity.
- Targets Bcl-2 family and Survivin.
- Involves the apoptosis pathway.
- Is a derivative of camptothecin.
Medchemexpress LLC Cn2 toxin TFA | 96.59% | 7588.60 | 5 MG
Cn2 toxin TFA (β-Mammal toxin Cn2 TFA) is a single-chain β-scorpion neurotoxic peptide identified as the main toxin found in scorpion venom. It specifically targets mammalian voltage-gated sodium channels (VGSC) Nav1.6.
- Single-chain β-scorpion neurotoxic peptide
- Main toxin in scorpion venom
- Specifically targets mammalian voltage-gated sodium channels (VGSC) Nav1.6
- Available in various quantities
- For research use only